secwatch.observer — SEC 8-K summary
======================================

Issuer:     CV Sciences, Inc. (CVSI)
CIK:        0001510964
Form:       8-K
Filed at:   2023-03-29T23:59:59+00:00
Accession:  0001510964-23-000012
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CV Sciences FY2022 revenue $16.2M, down 19% YoY; operating loss narrows to $6.8M
--------------------------------------------------------------------------------

- Revenue $16.2M for FY2022 vs $20.0M in 2021 (-19%); Q4 revenue $3.9M, up 3% sequentially.
- Gross margin 34.2% in FY2022 vs 43.0% in 2021; Q4 gross margin 40.4%.
- Operating expenses cut 54% to $12.4M; operating loss improved to $6.8M from $18.4M.
- Cash balance $0.6M at year-end; Q4 generated $0.2M positive operating cash flow.
- Regained #1 hemp extract brand in natural retail; launched new products; evaluating M&A.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1510964/000151096423000012/0001510964-23-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1510964/000151096423000012/cvsi-20230329.htm
  HTML page:      https://secwatch.observer/filing/0001510964-23-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer